[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643677":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":52,"collaborators":54,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":24,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":24,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":40,"whyStopped":24,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"The pregabalin group","EXPERIMENTAL","75 mg twice daily for 3 days, followed by 150 mg twice daily for 3 days during the first week; 225 mg twice daily at week 10; and a tapering regimen at week 12 (150 mg twice daily for 3 days, then 75 mg twice daily for 3 days). Patients also received routine treatment from gastroenterologists. Patients also received routine treatment from gastroenterologists. Loperamide: 2-4 mg after each loose stool (max 16 mg\u002Fday) to reduce stool frequency, though it does not relieve pain. Rifaximin: 550 mg TID for 14 days (repeatable); or Eluxadoline 100 mg BID (75 mg BID in post-cholecystectomy patients), which is contraindicated in pancreatitis or biliary obstruction. Antispasmodics: Dicyclomine: 10-20 mg QID or Hyoscyamine as needed for cramping.",[13,14],"Drug: The pregabalin group","Drug: Routine Treatment",{"label":16,"type":6,"description":17,"interventionNames":18},"The control group","The control group only received routine treatment from gastroenterologists. Patients also received routine treatment from gastroenterologists. Loperamide: 2-4 mg after each loose stool (max 16 mg\u002Fday) to reduce stool frequency, though it does not relieve pain. Rifaximin: 550 mg TID for 14 days (repeatable); or Eluxadoline 100 mg BID (75 mg BID in post-cholecystectomy patients), which is contraindicated in pancreatitis or biliary obstruction. Antispasmodics: Dicyclomine: 10-20 mg QID or Hyoscyamine as needed for cramping.",[14],[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","75 mg twice daily for 3 days, followed by 150 mg twice daily for 3 days during the first week; 225 mg twice daily at week 10; and a tapering regimen at week 12 (150 mg twice daily for 3 days, then 75 mg twice daily for 3 days).",[9],null,{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Routine Treatment","Patients also received routine treatment from gastroenterologists. Loperamide: 2-4 mg after each loose stool (max 16 mg\u002Fday) to reduce stool frequency, though it does not relieve pain. Rifaximin: 550 mg TID for 14 days (repeatable); or Eluxadoline 100 mg BID (75 mg BID in post-cholecystectomy patients), which is contraindicated in pancreatitis or biliary obstruction. Antispasmodics: Dicyclomine: 10-20 mg QID or Hyoscyamine as needed for cramping.",[16,9],[30],{"name":31,"affiliation":5,"role":32},"Fang Luo","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":24,"email":37},"CONTACT","+86 13611326978","13611326978@163.com",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":24},"RECRUITING","Beijing","Beijing Municipality","100050","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},{"type":32,"investigatorFullName":31,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Director of Department of Day surgery and Pain Management",[55,57,59],{"name":56,"class":6},"Hengshui People's Hospital",{"name":58,"class":6},"Hebei Medical University Third Hospital",{"name":60,"class":61},"Beijing Jianjia Rehabilitation Hospital","UNKNOWN","100643677","efficacy-of-pregabalin-for-patients-with-irritable-bowel-syndrome-100643677",false,"NCT07635394","Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome","Efficacy and Safety of Pregabalin in Patients With Irritable Bowel Syndrome : A Multi-center Prospective Randomized Open Blinded End-point Trial","Inclusion Criteria:\n\n1. Age range: 18-70 years old;\n2. According to the Rome IV diagnostic criteria for IBS, the screening result is positive;\n3. Mild to moderate IBS patients assessed based on the IBS-SSS.\n\nExclusion Criteria:\n\n1. Concurrent gastrointestinal conditions presenting with symptoms potentially overlapping with those of IBS, significant medical comorbidities;\n2. Severe mental disorders associated with marked personality disturbances, active suicidal thoughts or any self harm episodes within the preceding 12 months;\n3. Current or intended pregnancy or lactation;\n4. Cognitive impairment;\n5. Recent use of pregabalin (within 30 days) or known allergy to pregabalin;\n6. Concomitant use of medications that may interact with the study drug, mimic its effects, or aggravate expected adverse reactions (including but not limited to rosiglitazone, pioglitazone, opioids, anxiolytics, non opioid analgesics, mexiletine, dextromethorphan, and sedative hypnotics);\n7. Use of IBS specific agents such as alosetron;\n8. Consumption exceeding 50 units of alcohol weekly (where 1 unit corresponds to 10 mL of pure alcohol).","ALL","18 Years","70 Years",{"count":73,"type":74},258,"ESTIMATED","INTERVENTIONAL",[77],"NA","To explore the efficacy of pregabalin for patients with irritable bowel syndrome (IBS).",[80],"Irritable Bowel Syndrome (IBS)",[82,83],"Irritable Bowel Syndrome","pregabalin","2026-06-23",{"date":86,"type":87},"2026-06-25","ACTUAL",{"date":89,"type":87},"2026-04-07",{"date":91,"type":74},"2029-03-31",{"name":5,"class":6},1]